10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

SLAMF9 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP16284b

Specification

SLAMF9 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession Q96A28

SLAMF9 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 89886

Other Names
SLAM family member 9, CD2 family member 10, CD2F-10, CD84 homolog 1, CD84-H1, SLAMF9, CD2F10

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLAMF9 Antibody (C-term) Blocking Peptide - Protein Information

Name SLAMF9

Synonyms CD2F10

Function
May play a role in the immune response.

Cellular Location
Membrane; Single-pass type I membrane protein.

Tissue Location
Expression is predominantly restricted in hematopoietic tissues. Expressed in heart, spleen, liver, intestine, muscle and testis. Expressed in immune cells, including monocytes, dendritic, B- and T-cells. No expression was seen in peripheral blood leukocytes. Expressed in the leukocyte cell line THP-1

SLAMF9 Antibody (C-term) Blocking Peptide - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

SLAMF9 Antibody (C-term) Blocking Peptide - Images

SLAMF9 Antibody (C-term) Blocking Peptide - Background

SLAMF9 is a member of the signaling lymphocyticactivation molecule family. The encoded protein is a cell surfacemolecule that consists of two extracellular immunoglobulin domains,a transmembrane domain and a short cytoplasmic tail that lacks thesignal transduction motifs found in other family members.

SLAMF9 Antibody (C-term) Blocking Peptide - References

Calpe, S., et al. Adv. Immunol. 97, 177-250 (2008) :Fraser, C.C., et al. Immunogenetics 53 (10-11), 843-850 (2002) :Fennelly, J.A., et al. Immunogenetics 53(7):599-602(2001)Zhang, W., et al. Clin. Cancer Res. 7 (3 SUPPL), 822S-829S (2001) :